Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Aroa Biosurgery Ltd ( (AU:ARX) ) just unveiled an announcement.
Aroa Biosurgery Ltd has announced a change in its shareholder registry service provider from Boardroom Pty Ltd to Automic Pty Ltd, effective from June 2, 2025. This transition allows shareholders to manage their holdings more efficiently through Automic’s secure online investor portal, which offers features such as updating shareholder details and viewing transaction history. This change is expected to enhance shareholder engagement and streamline administrative processes, potentially improving the company’s operational efficiency and stakeholder satisfaction.
The most recent analyst rating on (AU:ARX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
More about Aroa Biosurgery Ltd
Aroa Biosurgery is a company specializing in soft-tissue regeneration, focusing on developing, manufacturing, and distributing medical and surgical products aimed at enhancing healing in complex wounds and soft tissue reconstruction. The company’s products are based on the proprietary AROA ECM™ technology platform, utilizing a novel extracellular matrix biomaterial derived from sheep forestomach. Aroa Biosurgery, founded in 2008 and headquartered in Auckland, New Zealand, distributes its products globally, with a significant market presence in the United States through its direct sales force and partnership with TELA Bio, Inc.
Average Trading Volume: 321,825
Technical Sentiment Signal: Sell
Current Market Cap: A$160.4M
For a thorough assessment of ARX stock, go to TipRanks’ Stock Analysis page.